FluidAI Medical Expands Portfolio with Acquisition of Emmetros Limited

FluidAI Medical Acquires Emmetros Limited to Enhance Patient Engagement Solutions

KITCHENER, ON—FluidAI Medical, a pioneer in medical technology that integrates hardware, software, and artificial intelligence (AI) solutions, announced a significant acquisition of Emmetros Limited, the developer behind the patient engagement platform SparxConnect. This strategic move aims to bolster FluidAI's existing offerings, particularly Stream Inara™, an AI-powered platform designed to extend surgical care beyond hospital environments, improving patient education and engagement throughout the recovery process.

This acquisition marks FluidAI's second strategic deal following the purchase of Medsix, further solidifying its growth strategy and enhancing its presence in the healthcare market with well-established products and technologies.

Stream Inara™ is integrated into FluidAI’s Recovery Intelligence and Surgical Excellence (RISE) Program, a comprehensive initiative focusing on quality improvement in surgical care. The RISE program is tailored to enable Enhanced Recovery After Surgery (ERAS) protocols, covering the entire surgical journey. It incorporates various components, including Stream Care™, an AI-assisted Surgical Expert Suite; Origin™, an FDA-cleared monitoring device; and Stream Inara™ for patient engagement after discharge.

Designed to facilitate patient recovery at home, Stream Inara™ functions as a digital management tool by monitoring patients post-discharge, gathering patient-reported outcomes, and providing customized educational resources and 24/7 support. This initiative aims to enhance adherence to care plans and assist patients in a smooth recovery. By integrating Stream Inara™ into the RISE Program, FluidAI seeks to support early patient discharge, thereby optimizing hospital resources and patient throughput, while ensuring continuous patient engagement during recovery.

Mary Pat Hinton, CEO and co-founder of Emmetros, expressed her excitement about the acquisition, stating it represents a significant advancement for their technology and mission. She emphasized FluidAI's commitment to improving surgical patient outcomes through innovation and noted the synergy between their capabilities in real-time monitoring and Emmetros’ customizable patient engagement solutions.

FluidAI CEO Youssef Helwa echoed this sentiment, highlighting Emmetros’ dedication to patient-centric care. He reiterated that the acquisition aligns with FluidAI’s mission to redefine surgical care standards and enhance patient outcomes during recovery, paving the way for safer early discharges after general and gastrointestinal surgeries.

Founded in 2014, FluidAI Medical is committed to transforming surgical care using real-time data. The company specializes in developing monitoring and digital platforms that convert previously unutilized data into actionable insights for clinicians, enabling timely interventions, accurate decision-making, and improved patient outcomes. Its product suite includes Origin™, the Stream Care™ platform, Stream Inara™, and Stream CMx™, a clinical documentation tool.

Emmetros Limited, also founded in 2014, stands out in inclusive healthcare technology with SparxConnect, which provides a secure and customizable platform for healthcare providers, enhancing personalized care for patients, families, and care teams.

FluidAI Medical continues to position itself as a leader in the medical technology space, leveraging strategic acquisitions to broaden its impact on patient care and outcomes. For the latest updates, FluidAI encourages interested parties to follow them on LinkedIn or visit their website.